Oorsprong van het eerstegraads netwerk van Kim Raineri
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
| Public Company | Biotechnology | 8 | |
| Public Company | Medical Specialties | 4 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Kim Raineri via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| University College London | College/University | Corporate Officer/Principal Undergraduate Degree | |
ImmuneBridge, Inc.
 ImmuneBridge, Inc. BiotechnologyHealth Technology ImmuneBridge, Inc. is a biotech company that is developing the next generation of allogeneic cellular medicines to make curative cancer therapies accessible to everyone. The company is based in San Francisco, CA and was founded in 2018 by Jesse Cotari and Peretz Partensky. The company is starting with NK cell-based immunotherapies. The company's proprietary expansion technology amplifies cord blood-derived immune stem cells while maintaining full immune multipotency to create a consistent and abundant cellular source for immunotherapies. ImmuneBridge's scientific approach harnesses this expansion technology along with the unique benefits of umbilical cord blood to enable robust screening and selection for the most potent cancer-fighting cells. Peretz Partensky has been the CEO since 2018. | Biotechnology | Director/Board Member | |
| KRYSTAL BIOTECH, INC. | Biotechnology | Director/Board Member | |
Oribiotech Ltd.
 Oribiotech Ltd. BiotechnologyHealth Technology Oribiotech Ltd. Engages in Cell and Gene Therapy (CGT) manufacturing. The company was founded by Farlan Veraitch and Chris Mason on September 2, 2015 and is headquartered in London, the United Kingdom. | Biotechnology | Founder | |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | General Counsel | |
Freeline Therapeutics Ltd.
 Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Freeline Therapeutics Ltd. operates as a biopharmaceutical company, which develops gene therapies for bleeding and other debilitating disorders. The company was founded by Chris Hollowood in 2015 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | General Counsel | |
| SIO GENE THERAPIES INC. | Pharmaceuticals: Major | Public Communications Contact | |
| BLUEBIRD BIO, INC. | Biotechnology | General Counsel | |
| Boston University | College/University | Undergraduate Degree | |
| LYSOGENE | Miscellaneous Commercial Services | General Counsel | |
Horizon Education LLC
 Horizon Education LLC Miscellaneous Commercial ServicesCommercial Services Horizon Education LLC builds sustainable SAT/ACT programs for schools and organizations. The company is based in Laguna Beach, CA. The company provides professional development, personalized curriculum, and assessments for teachers and students. The company was founded in 2013 by Dustin Bainbridge and Michelle Sauceda. Dustin Bainbridge has been the CEO since 2013. Horizon Education was acquired by Progress Learning LLC on June 23, 2022. | Miscellaneous Commercial Services | Chief Operating Officer | |
| Imperial College London | College/University | Undergraduate Degree | |
| University of Maryland | College/University | Doctorate Degree | |
Poietic Technologies, Inc.
 Poietic Technologies, Inc. Chemicals: SpecialtyProcess Industries Part of Cambrex Corp., Poietic Technologies, Inc. supplies normal human cells of hematopoietic origin. The company is based in Gaithersburg, MD. The company was founded by Kim Warren. Poietic Technologies was acquired by Cambrex Corp. on December 28, 1998 for $2.50 million. | Chemicals: Specialty | Founder | |
| CAMBREX CORPORATION | Pharmaceuticals: Generic | Chief Tech/Sci/R&D Officer | |
Centre For Commercialization of Regenerative Medicine
 Centre For Commercialization of Regenerative Medicine BiotechnologyHealth Technology Centre For Commercialization of Regenerative Medicine supports our partners to develop and commercialize cell and gene therapies and regenerative medicine technologies. Its services include business, technical and facilities. The company is headquartered in Toronto, Canada. | Biotechnology | Chief Tech/Sci/R&D Officer | |
Lonza Walkersville, Inc.
 Lonza Walkersville, Inc. Pharmaceuticals: MajorHealth Technology Lonza Walkersville, Inc. develops, manufactures and provides testing services for cell-based therapeutics. Its services include life-science customers, research organizations, pharmaceutical, biopharmaceutical, biotechnology and generic drug companies. The company was founded was founded on May 9, 1991 and is headquartered in Walkersville, MD. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| PROMIS NEUROSCIENCES, INC. | Biotechnology | Chief Executive Officer | |
FAAH Pharma, Inc.
 FAAH Pharma, Inc. BiotechnologyHealth Technology FAAH Pharma, Inc. operates as a project-focused company developing a clinical asset initially for postherpetic neuralgia. The company was founded on June 26, 2014 and is headquartered in Montreal, Canada. | Biotechnology | Director/Board Member | |
| DURECT CORPORATION | Pharmaceuticals: Major | Director/Board Member | |
| King's College London | College/University | Doctorate Degree | |
| PRGX GLOBAL, INC. | Miscellaneous Commercial Services | Chairman | |
Zogenix International Ltd.
 Zogenix International Ltd. Pharmaceuticals: MajorHealth Technology Zogenix International Ltd. manufactures and markets pharmaceutical products. It develops Brabafen an oral treatment for use in children with Dravet Syndrome or severe myoclonic epilepsy of infancy. The company was founded in 2012 and is headquartered in Maidenhead, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
| George Washington University School of Medicine & Health | College/University | Corporate Officer/Principal | |
| Boston University School of Law | College/University | Graduate Degree | |
| Dickinson College | College/University | Undergraduate Degree | |
| SENSEI BIOTHERAPEUTICS, INC. | Biotechnology | General Counsel | |
| SANGAMO THERAPEUTICS, INC. | Biotechnology | Chief Tech/Sci/R&D Officer | |
| UCL Medical School | College/University | Doctorate Degree | |
| Royal Free Hospital Medical School | College/University | Doctorate Degree | |
| The Royal College of Physicians | College/University | Corporate Officer/Principal | |
Children's National Hospital (District of Columbia)
 Children's National Hospital (District of Columbia) Hospital/Nursing ManagementHealth Services Children's Hospital is a non-profit organization which engages in the provision of healthcare services. It offers pediatric and adolescent services, cardiac surgery, colorectal program, neurosurgery, oncology, and orthopedic surgery and sports medicine. The company was founded in 1870 and is headquartered in Washington, DC. | Hospital/Nursing Management | Corporate Officer/Principal | |
| The Johns Hopkins University | College/University | Corporate Officer/Principal | |
| London Regenerative Medicine Network Ltd. | Founder | ||
| CINRG | Founder | ||
Akashi Therapeutics Inc
 Akashi Therapeutics Inc Pharmaceuticals: MajorHealth Technology Akashi Therapeutics Inc is a clinical stage biopharmaceutical company based in Cambridge, MA with subsidiaries in the United States. The private company has been granted orphan designation for DMD in both the US and Europe. The American company's mission is to develop treatments for Duchenne muscular dystrophy and other rare pediatric diseases. Akashi is developing a cocktail of medications with the goal of transforming Duchenne from a 100% fatal, aggressive muscle-wasting disease to a chronic, manageable condition. The application of HT-100 to DMD and other fibrotic diseases is based on pioneering work by Dr. Mark Pines at the Volcani Institute. Dosing and new patient enrollment in the phase 1b/2a clinical program have been suspended. The company was founded by leading patient organizations and biotechnology industry veterans and is managed by a seasoned team of drug development experts. The company was founded by Marc B. Blaustein, Thomas C. Wicka. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| Universidad de Buenos Aires | College/University | Doctorate Degree | |
| VIRIDIAN THERAPEUTICS, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Alliance for Regenerative Medicine
 Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. | Medical/Nursing Services | Director/Board Member | |
| UK Stem Cell Foundation | Investment Trusts/Mutual Funds | Director/Board Member | |
| The British Neurological Research Trust | Director/Board Member | ||
| Stem Cell Translation Ltd. | Founder | ||
| American Society For Experimental Neurotherapeutics | Director/Board Member | ||
| ZOGENIX, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| St. Louis University | College/University | Director/Board Member | |
| Duquesne University of The Holy Spirit | College/University | Undergraduate Degree | |
US Food & Drug Administration
 US Food & Drug Administration General GovernmentGovernment US Food & Drug Administration operates agencies to protect health and human services. It protects and promotes public health through the control and supervision of food safety, tobacco products, dietary supplements, prescription and over-the-counter pharmaceutical drugs, vaccines, biopharmaceuticals, blood transfusions, medical devices, electromagnetic radiation emitting devices, cosmetics, animal foods and feed and veterinary products. The company was founded by Theodore Roosevelt and Harvey Washington Wiley on 30th June, 1906 and is headquartered in Silver Spring, MD. | General Government | Corporate Officer/Principal | |
| Georgetown University | College/University | Graduate Degree | |
| Wayne State University (Michigan) | College/University | Doctorate Degree |
Statistieken
Internationaal
| Verenigde Staten | 31 |
| Verenigd Koninkrijk | 14 |
| Canada | 4 |
| Israël | 2 |
| Frankrijk | 2 |
Sectoraal
| Health Technology | 20 |
| Consumer Services | 18 |
| Commercial Services | 4 |
| Health Services | 3 |
| Process Industries | 2 |
Operationeel
| Director/Board Member | 31 |
| Corporate Officer/Principal | 18 |
| Chief Tech/Sci/R&D Officer | 17 |
| General Counsel | 11 |
| Founder | 9 |
Sterkste connecties
| Insiders | |
|---|---|
| Gail Farfel | 15 |
| Birgitte Volck | 13 |
| Christopher Mason | 12 |
| Thomas J. Lynch | 9 |
| John M. Cook | 8 |
| Kim Warren | 8 |
| Diana M. Escolar | 8 |
| Daniel Bevevino | 7 |
| Sean O'Bryan | 7 |
| Essra Ridha | 6 |
| Thomas Ackerman | 5 |
| Christopher Gerry | 5 |
- Beurs
- Insiders
- Kim Raineri
- Bedrijfsconnecties
